Group 1 - The fund contract of the Sino-Canadian Medical Innovation Mixed Initiation Securities Investment Fund has been terminated as per the relevant regulations and the fund contract provisions [1][2] - The fund management company has completed the fund asset liquidation process from December 1, 2025, to January 20, 2026, without the need for a meeting of fund shareholders [1][2] - The liquidation report was published on February 11, 2026, after being filed with the China Securities Regulatory Commission [1][2] Group 2 - The total remaining assets to be distributed amount to RMB 12,025,076.10, which will be allocated to fund shareholders in cash based on their shareholding proportions as of the last operating day [2] - The distribution of remaining assets will occur on February 25, 2026, from the fund's custody account [2] - After the distribution is completed, the fund management company will proceed with account cancellation and other related tasks as per legal regulations [2]

Core Viewpoint - The China-Canada Medical Innovation Mixed Fund has triggered termination conditions as its net asset value fell below 200 million RMB, leading to the initiation of the fund's liquidation process without the need for a shareholder meeting [2]. Fund Establishment and Termination - The China-Canada Medical Innovation Mixed Fund was officially established on November 30, 2022, after being registered [1]. - According to the fund contract, if the net asset value is below 200 million RMB three years after the contract's effective date, the fund will automatically terminate [2]. - The effective date of the fund contract is November 30, 2022, and the termination condition will be assessed on November 30, 2025 [2]. Fund Performance - As of the last disclosed net value date on December 1, 2025, the cumulative net value for Class A and Class C shares were 0.8135 RMB and 0.7996 RMB, respectively, with cumulative returns of -18.63% and -20.02% [2]. - The fund's performance in the current year shows a growth of 8.22% for Class A and 7.64% for Class C, while the one-year performance remains negative [4][5]. - The average return for similar funds is significantly higher at 33.12%, indicating underperformance relative to peers [4][5].

Group 1 - The core viewpoint of the announcement is that Zhongjia Fund Management Co., Ltd. will suspend subscription (including transfer-in and regular investment) for the Zhongjia Medical Innovation Mixed Fund starting from November 14, 2025, to protect the interests of fund shareholders [1] Group 2 - The announcement includes details about the specific sub-funds affected, including Zhongjia Medical Innovation Mixed Initiation A (code: 016756) and Zhongjia Medical Innovation Mixed Initiation C (code: 016757) [1] - The announcement indicates that the suspension applies to large-scale subscriptions, transfers, redemptions, and regular investments for the mentioned sub-funds [1]